Several new treatments are transforming diabetes management, with Retatrutide, Cagrillintide, Tirzepatide, and Semaglutide emerging as potential options. Retatrutide, a double GIP and GLP-1 target activator, exhibits substantial fat reduction and enhanced glycemic levels. Cagrillintide, a GLP-1 activator, is now in clinical trials, suggesting encou